Once-Daily Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults

被引：0
|
作者：
Lall, Ayesha S. [1 ]
Averbuch, Robert [1 ]
机构：
[1] Univ Florida, Dept Psychiat, Gainesville, FL 32610 USA
来源：
CURRENT PSYCHIATRY REPORTS | 2010年 / 12卷 / 05期
关键词：
ADHD;
D O I：
10.1007/s11920-010-0137-3
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：363 / 365
页数：3
相关论文
共 50 条
  • [21] Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study
    Michelson, D
    Allen, AJ
    Busner, J
    Casat, C
    Dunn, D
    Kratochvil, C
    Newcorn, J
    Sallee, FR
    Sangal, RB
    Saylor, K
    West, S
    Kelsey, D
    Wernicke, J
    Trapp, NJ
    Harder, D
    AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11): : 1896 - 1901
  • [22] Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder
    Bangs, Mark E.
    Hazell, Philip
    Danckaerts, Marina
    Hoare, Peter
    Coghill, David R.
    Wehmeier, Peter M.
    Williams, David W.
    Moore, Rodney J.
    Levine, Louise
    PEDIATRICS, 2008, 121 (02) : E314 - E320
  • [23] Atomoxetine in the Treatment of Adolescent With Trichotillomania and Attention-Deficit/Hyperactivity Disorder
    Turkoglu, Serhat
    Cetin, Fatih Hilmi
    CLINICAL NEUROPHARMACOLOGY, 2018, 41 (02) : 84 - 85
  • [24] Effectiveness and safety of the once-daily OROS formulation of methylphenidate in adolescents with attention-deficit/hyperactivity disorder
    Biederman, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S448 - S448
  • [25] Once-daily OROS® methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder
    McGough, James J.
    McBurnett, Keith
    Bukstein, Oscar
    Wilens, Timoth E.
    Greenhill, Laurence
    Lerner, Marc
    Stein, Mark
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (03) : 351 - 356
  • [26] Treatment of attention-deficit/hyperactivity disorder with a once-daily formulation of MPH: A two-year effectiveness trial
    Stein, MA
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S414 - S415
  • [27] A review of amphetamine extended release once-daily options for the management of attention-deficit hyperactivity disorder
    Abbas, Kendall
    Barnhardt, Elizabeth W.
    Nash, Patricia L.
    Streng, Maria
    Coury, Daniel L.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (04) : 421 - 432
  • [28] Effects of atomoxetine treatment on executive functioning in adults with attention-deficit/hyperactivity disorder (ADHD)
    Biederman, J
    Faraone, S
    Spencer, T
    Michelson, D
    Jones, D
    Adler, L
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S458 - S458
  • [29] Treatment of Adults With Attention-Deficit/Hyperactivity Disorder
    Baron, David A.
    Pato, Michele T.
    Cyr, Rebecca L
    JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2011, 111 (11): : 610 - 614
  • [30] Hepatic Events Associated with Atomoxetine Treatment for Attention-Deficit Hyperactivity Disorder
    Mark E. Bangs
    Ling Jin
    Shuyu Zhang
    Durisala Desaiah
    Albert J. Allen
    Holly A. Read
    Arie Regev
    Joachim F. Wernicke
    Drug Safety, 2008, 31 : 345 - 354
12345